PEP-Therapy: Funding, Investors & Team (Sep 2026)
PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.
PEP-Therapy has raised $5.2M across 2 funding rounds on record, the most recent a Series A of $1.9M announced in Jul 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
PEP-Therapy Company Profile and Key Stats
Latest funding round on record: Jul 2021.
PEP-Therapy Funding Rounds
PEP-Therapy raised $3.3M in a Series A announced in Apr 2021.
3 months later, a Series A of $1.9M was announced in Jul 2021.
PEP-Therapy Founders and Leadership Team
Contact details for the PEP-Therapy team: 1 of 1 has an email address on file.
Start 14-day free trial →PEP-Therapy Funding Compared to Other Biotechnology Startups
PEP-Therapy's latest round of $1.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like PEP-Therapy in Biotechnology and Évry
Companies Similar to PEP-Therapy
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
PEP-Therapy Funding FAQs
What does PEP-Therapy do?
PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.
How much funding has PEP-Therapy raised?
PEP-Therapy has raised $5.2M across 2 rounds on record. The most recent is a Series A of $1.9M announced in Jul 2021.
When did PEP-Therapy last raise funding?
PEP-Therapy's most recent funding round on record is a Series A of $1.9M, announced in Jul 2021.
Who is the CEO of PEP-Therapy?
Antoine Prestat is listed as CEO at PEP-Therapy.
Where is PEP-Therapy headquartered?
PEP-Therapy is based in Évry, Ile-De-France, France.
How many employees does PEP-Therapy have?
PEP-Therapy is in the 1-10 employee band.
How does PEP-Therapy's funding compare to other Biotechnology startups?
PEP-Therapy's latest round of $1.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's PEP-Therapy Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for PEP-Therapy is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.